Liu Guangchao, Lin Wenlong, Zhang Kaifeng, Chen Kangxu, Niu Guanglin, Zhu Yonghao, Liu Yixuan, Li Pengkun, Li Zhihao, An Yang
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Henan University, Kaifeng, 475004, China; School of Stomatology, Henan University, Kaifeng, 475004, China.
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Henan University, Kaifeng, 475004, China; Henan Provincial Engineering Center for Tumor Molecular Medicine, Kaifeng Key laboratory of cell signal transduction, Henan University, Kaifeng, 475004, China.
Cancer Genet. 2024 Nov;288-289:68-81. doi: 10.1016/j.cancergen.2024.10.005. Epub 2024 Oct 18.
Topoisomerase IIα (TOP2A) is a crucial enzyme that plays a vital role in DNA replication and transcription mechanisms. Dysregulated expression of TOP2A has been associated with various malignancies, including hepatocellular carcinoma, prostate cancer, colon cancer, lung cancer and breast cancer. In this review, we summarized the prognostic relevances of TOP2A in various types of cancer. The increased expression of TOP2A has been linked to resistance to therapy and reduced survival rates. Therefore, evaluating TOP2A levels could assist in identifying patients who may derive advantages from molecular targeted therapy. The amplification of TOP2A has been linked to a positive response to chemotherapy regimens that contain anthracycline. Nevertheless, the overexpression of TOP2A also indicates a heightened likelihood of disease recurrence and unfavorable prognosis. The prognostic significance of TOP2A has been extensively studied in various types of cancer. The increased expression of TOP2A is associated with poor clinical outcomes, indicating its potential as a valuable biomarker for assessing risk and stratifying treatment in these malignancies. However, further investigation is needed to elucidate the underlying mechanisms by which TOP2A influences cancer progression and to explore its potential as a therapeutic target.
拓扑异构酶IIα（TOP2A）是一种关键酶，在DNA复制和转录机制中发挥着至关重要的作用。TOP2A的表达失调与多种恶性肿瘤相关，包括肝细胞癌、前列腺癌、结肠癌、肺癌和乳腺癌。在本综述中，我们总结了TOP2A在各种类型癌症中的预后相关性。TOP2A表达增加与治疗耐药性和生存率降低有关。因此，评估TOP2A水平有助于识别可能从分子靶向治疗中获益的患者。TOP2A的扩增与对含蒽环类化疗方案的阳性反应有关。然而，TOP2A的过表达也表明疾病复发的可能性增加和预后不良。TOP2A的预后意义已在各种类型的癌症中得到广泛研究。TOP2A表达增加与不良临床结果相关，表明其作为评估这些恶性肿瘤风险和分层治疗的有价值生物标志物的潜力。然而，需要进一步研究以阐明TOP2A影响癌症进展的潜在机制，并探索其作为治疗靶点的潜力。
